Oncolytic Peptide LTX-315 Targets PD-L1 to Boost Anti-Tumor Immunity in Cancer | Research

The takeaway

The oncolytic peptide LTX-315 targets PD-L1 on cancer cells to improve anti-tumor immune response, combining direct tumor killing with immune checkpoint modulation in a single molecule.

Kill + unmask
LTX-315 both kills cancer cells and removes their PD-L1 immune shield — combining two therapeutic functions in a single peptide

What the researchers found

LTX-315 targets PD-L1 on cancer cells, combining direct oncolytic (membrane-disrupting) activity with immune checkpoint modulation for dual anti-tumor mechanism.

Why it matters

Combining tumor killing with immune checkpoint modulation in a single peptide could eliminate the need for costly antibody-drug combinations.

How the study worked

In vitro and in vivo evaluation of LTX-315 PD-L1 targeting, oncolytic activity, and anti-tumor immune response modulation.

What this study cannot tell us

Preclinical. PD-L1 targeting mechanism needs fuller characterization. Clinical development status uncertain.

How to read the evidence

Preclinical study with dual mechanism characterization.

When this study was published

Published in 2025.

The bigger picture

A peptide that kills tumors AND unmasks them to the immune system represents the ideal single-molecule cancer immunotherapy.

Questions still open

Would LTX-315 synergize with anti-PD-1 antibodies?
Could it be combined with anti-CTLA-4 for broader immune activation?
What is LTX-315's clinical development status?

Common questions

How does one peptide fight cancer two ways?

LTX-315 physically destroys cancer cell membranes (direct killing) AND removes PD-L1 (the protein cancers use to hide from the immune system), allowing immune cells to recognize and attack the tumor.

Is this like a checkpoint inhibitor?

It combines checkpoint inhibition with direct tumor killing in a single small peptide — potentially simpler and cheaper than combining separate antibody drugs.

Read the original research

Oncolytic peptide LTX-315 targets PD-L1 to improve antitumor immune response of nanosecond pulse electric field in liver cancer.

Journal for immunotherapy of cancer, 14(1)

View on PubMed ↗Publisher’s paper ↗

Citation

Ji, Kun; Jing, Li; Xu, Tiantian; Cao, Shoujin; Zhang, Cong; Wang, Zilin; Zhou, Guanhui; Cao, Yunbo; Niu, Jiahua; Yang, Yuning; Chen, Xinhua; Ai, Jing; Sun, Jun-Hui; Xiong, Bin. (2026). Oncolytic peptide LTX-315 targets PD-L1 to improve antitumor immune response of nanosecond pulse electric field in liver cancer.. Journal for immunotherapy of cancer, 14(1). https://doi.org/10.1136/jitc-2025-012438